Country: Spain
Language: English
Source: HMA (Heads of Medicines Agencies)
marbofloxacin 20 mg
Krka d.d.
QJ01MA93
Tablet
marbofloxacin
Dogs
2012-11-21
Issued: April 2013 AN: 01880/2011 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marfloxin 20 mg tablets for dogs Quiflox 20 mg tablets for dogs Quiflox vet 20 mg tablets for dogs Marbiflox 20 mg tablets for dogs Marfloxin 20 mg tablets for dogs (Austria, Belgium, Bolgaria, Estonia, Germany, Greece, Italy, Ireland, Netherlands, Poland, Portugal, Romania, Slovenia, Spain, United Kingdom) Quiflox 20 mg tablets for dogs (Czech Republic, Hungary, Latvia, Lithuania, Slovak Republic, Quiflox vet 20 mg tablets for dogs (Norway, Sweden, Finland) Marbiflox 20 mg tablets for dogs (Denmark, France) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Marbofloxacin …….20 mg EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. Light brownish yellow, round, biconvex, marble tablets with bevelled edges and with possible dark and white spots, scored on one side. The tablets can be divided into halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin in dogs: skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis); urinary tract infections (UTI) associated or not with prostatitis or epididymitis; respiratory tract infections. Issued: April 2013 AN: 01880/2011 Page 2 of 6 4.3 CONTRAINDICATIONS Do not use in dogs aged less than Read the complete document